Invention Grant
- Patent Title: Coronavirus vaccine
-
Application No.: US17231261Application Date: 2021-04-15
-
Publication No.: US11241493B2Publication Date: 2022-02-08
- Inventor: Susanne Rauch , Hans Wolfgang Große , Benjamin Petsch
- Applicant: CureVac AG
- Applicant Address: DE Tübingen
- Assignee: CureVac AG
- Current Assignee: CureVac AG
- Current Assignee Address: DE Tübingen
- Agency: Parker Highlander PLLC
- Priority: WOPCT/EP2020/052775 20200204
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/215 ; A61K45/06 ; A61P31/14 ; C07K16/10 ; A61K47/69 ; A61K47/26 ; C12N7/00

Abstract:
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
Public/Granted literature
- US20210379181A1 CORONAVIRUS VACCINE Public/Granted day:2021-12-09
Information query